Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase I data presented at ASCO for L-377202, a peptide conjugate of doxorubicin

May 25, 2000

ASCO news: polymeric CPT derivative assessed in phase I for toxicity and pharmacokinetics

May 25, 2000

Lipophilic camptothecin derivatives with favorable profile of activity, toxicity

May 25, 2000

AstraZeneca develops new treatments for cancer, rheumatoid arthritis, etc.

May 25, 2000

Oregon State U. researchers disclose curacin A derivatives with improved stability

May 25, 2000

TNP-470 delays gastric ulcer healing in rats

May 25, 2000

GTI-2040 phase I/II trial on target for completion by year-end

May 25, 2000

Proteasome inhibitor MG-132 endowed with antineoplastic activity

May 25, 2000

DDW presentations support efficacy of exisulind in FAP and related conditions

May 24, 2000

Inhibitors of cyclin-dependent kinases claimed by DuPont for cancer

May 24, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...